Bioverativ

bioverativ.com

Bioverativ is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders. We have a leading portfolio of hemophilia therapies and an innovative pipeline of programs in hemophilia, sickle cell disease and beta thalassemia.

Related News

BIOGEN ANNOUNCES EFFECTIVENESS OF BIOVERATIV FORM 10 REGISTRATION STATEMENT

Biogen | December 22, 2016

news image

Biogen Inc. (NASDAQ: BIIB) today announced that the U.S. Securities and Exchange Commission (SEC) has declared effective the Registration Statement on Form 10 filed by Bioverativ Inc. Biogen expects to complete the separation of Bioverativ into an independent, global biotechnology company focused on hemophilia and other rare blood disorders on February 1, 2017....

Read More

BIOGEN AND SPIN-OFF BIOVERATIV WILL PRESENT AT THE GOLDMAN SACHS HEALTHCARE CEOS UNSCRIPTED CONFERENCE

Biogen | December 21, 2016

news image

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Goldman Sachs Healthcare CEOs Unscripted Conference. The webcast will be live on Thursday, January 5, 2017 at 4:00p.m. ET. Additionally, Bioverativ, the planned spin-off of Biogen’s hemophilia business, will present as well. That webcast will be live on Thursday, January 5, 2017 at 3:15p.m. ET. To access the live webcasts, please visit Biogen’s Investors section at www.biogen.com/investors. An archived version of ...

Read More

BIOGEN ANNOUNCES ADDITIONAL MEMBERS OF MANAGEMENT TEAM OF HEMOPHILIA SPIN-OFF COMPANY BIOVERATIV

Biogen | November 15, 2016

news image

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Goldman Sachs Healthcare CEOs Unscripted Conference. The webcast will be live on Thursday, January 5, 2017 at 4:00p.m. ET. Additionally, Bioverativ, the planned spin-off of Biogen’s hemophilia business, will present as well. That webcast will be live on Thursday, January 5, 2017 at 3:15p.m. ET. The planned spin-off of Bioverativ is expected to be completed on February 1, 2017....

Read More

BIOVERATIV, BICYCLE IN TANDEM FOR $424M-PLUS BLOOD DISEASE R&D PACT

fiercebiotech | September 06, 2017

news image

Biogen’s newly spun off hemophilia biotech Bioverativ has signed a new pact with U.K. biotech Bicycle Therapeutics. The pair will ride tandem on new research work for hemophilia and sickle cell disease with the help of the biotech’s bicyclic peptide platform (the eponymous Bicycle). Bicycles combine attributes of antibodies, small molecules and peptides within one molecule, which the company says should allow “high selectivity and affinity” while at the same time being ab...

Read More
news image

BIOGEN ANNOUNCES EFFECTIVENESS OF BIOVERATIV FORM 10 REGISTRATION STATEMENT

Biogen | December 22, 2016

Biogen Inc. (NASDAQ: BIIB) today announced that the U.S. Securities and Exchange Commission (SEC) has declared effective the Registration Statement on Form 10 filed by Bioverativ Inc. Biogen expects to complete the separation of Bioverativ into an independent, global biotechnology company focused on hemophilia and other rare blood disorders on February 1, 2017....

Read More
news image

BIOGEN AND SPIN-OFF BIOVERATIV WILL PRESENT AT THE GOLDMAN SACHS HEALTHCARE CEOS UNSCRIPTED CONFERENCE

Biogen | December 21, 2016

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Goldman Sachs Healthcare CEOs Unscripted Conference. The webcast will be live on Thursday, January 5, 2017 at 4:00p.m. ET. Additionally, Bioverativ, the planned spin-off of Biogen’s hemophilia business, will present as well. That webcast will be live on Thursday, January 5, 2017 at 3:15p.m. ET. To access the live webcasts, please visit Biogen’s Investors section at www.biogen.com/investors. An archived version of ...

Read More
news image

BIOGEN ANNOUNCES ADDITIONAL MEMBERS OF MANAGEMENT TEAM OF HEMOPHILIA SPIN-OFF COMPANY BIOVERATIV

Biogen | November 15, 2016

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Goldman Sachs Healthcare CEOs Unscripted Conference. The webcast will be live on Thursday, January 5, 2017 at 4:00p.m. ET. Additionally, Bioverativ, the planned spin-off of Biogen’s hemophilia business, will present as well. That webcast will be live on Thursday, January 5, 2017 at 3:15p.m. ET. The planned spin-off of Bioverativ is expected to be completed on February 1, 2017....

Read More
news image

BIOVERATIV, BICYCLE IN TANDEM FOR $424M-PLUS BLOOD DISEASE R&D PACT

fiercebiotech | September 06, 2017

Biogen’s newly spun off hemophilia biotech Bioverativ has signed a new pact with U.K. biotech Bicycle Therapeutics. The pair will ride tandem on new research work for hemophilia and sickle cell disease with the help of the biotech’s bicyclic peptide platform (the eponymous Bicycle). Bicycles combine attributes of antibodies, small molecules and peptides within one molecule, which the company says should allow “high selectivity and affinity” while at the same time being ab...

Read More